NeOnc Technologies Holdings is trading 13.31% up at $3.97 after confirming an August 12 presentation of topline Phase 2a NEO100 results in recurrent high-grade glioma.

  • August 10 second-quarter results showed a $14.2 million net loss and sharply higher research spending.
  • Management emphasized the imminent clinical readout.
  • The broader market is nearly flat, making company news the likeliest driver.